Ascletics' Novel HCV Treatment is Approved by CFDA

06:36 EDT 14 Jun 2018 | ChinaBio Today

Ascletis Pharma of Hangzhou reported that its lead drug, Ganovo® (danoprevir), an innovative treatment for hepatitis C, was approved by the CFDA. Ganovo is the first direct-acting anti-viral agent (DAA) developed by a China company to be approved. Ganovo works by inhibiting the NS3/4A protease that is critical to HCV replication. Ascletis plans to combine Ganovo with another of its candidates, ravidasir, to offer an all-oral HCV treatment with a near-100% cure rate. One month ago, Ascletis filed to stage an IPO on the Hong Kong exchange. More details....

Share this with colleagues:

Original Article: Ascletics' Novel HCV Treatment is Approved by CFDA


More From BioPortfolio on "Ascletics' Novel HCV Treatment is Approved by CFDA"

Quick Search


Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...